The UK is exploring the voluntary use of libido-suppressing medication for some male prisoners convicted of sex offences in England and Wales, according to expert evaluation and reporting. Prof Belinda Winder says the approach could begin in prisons from December 2028 and may expand to around 20 prisons, with a possible wider rollout by late 2028.
The discussion centers on treatment for prisoners assessed as having problematic sexual arousal (PSA). The reporting estimates that about one in four sex offenders—around 3,750 current prisoners—could be considered for the medication. Outlets also describe that similar requirements already exist for some sex offenders in other countries, often through parole conditions or risk-management frameworks.
While the proposal is framed as voluntary, some views presented in the coverage question whether chemical suppression is ethical. The differing angles focus on potential public protection and clinical rationale versus concerns about consent, human rights, and long-term implications of suppressing sexual drive through medication.
